A large number of different medication groups are used in the treatment of neuropathic pain including gabapentinoids. Besides neuropathic pain, these medications cover a wide range of indications from epilepsy, anxiety, depression, bipolar disorder, etc. As these conditions might carry different risks for the pregnancy, independent of the medications prescribed, it is important to be able to distinguish the reason for their prescribing. Moreover, there are limited data on the safety of use of pregabalin and gabapentin during pregnancy. The project will be divided into three parts: 1. The methodological study aims to develop a general conceptual framework to disentangle the different indications of medications in large healthcare data sources. The methodology will be developed on medications used to treat neuropathic pain. 2. Drug utilisation study aims to characterize the prescription pattern of medications used to treat neuropathic pain among women of childbearing age and pregnant women, focusing on those with limited information regarding the safety profile during pregnancy such as pregabalin and gabapentin. The cohort study will be based on at least 11 data sources, covering 6 at least European countries:France, Finland, Norway, Italy, UK, Germany (approx. 17.7 million pregnancies.) A case-malformed control study will be also performed using the Euromedicat Central database (around 10,5 million pregnancies) 3. Drug safety study aims to assess the association between prenatal exposure to neuropathic pain medications (especially pregabalin and gabapentin) and adverse pregnancy outcomes, including major congenital anomalies, stillbirth, preterm birth, low birth weight, small for gestational age, and long-term neurodevelopmental outcomes. Women aged between 15 and 49 y, from 1 January 2006 to the most recent date of each data source where medications and outcomes data are available wll be studied.